Home/Pipeline/NPT 2042

NPT 2042

Epilepsy

Phase 2Active

Key Facts

Indication

Epilepsy

Phase

Phase 2

Status

Active

Company

NeuroPro Therapeutics

About NeuroPro Therapeutics

NeuroPro Therapeutics is a private, clinical-stage company leveraging a de-risked drug development strategy by creating novel analogs of FDA-approved loop diuretics. Its lead candidate, NPT 2042, is an NKCC antagonist being developed for epilepsy, with Phase 2 trials planned for 2024, aiming to address the significant unmet need in the 30% of patients with drug-resistant seizures. The company's platform is built on foundational research from founder Daryl Hochman, demonstrating proof of efficacy in preclinical models without the diuretic side effect. NeuroPro's mission is to redefine neurological care by improving efficacy and tolerability for a range of brain disorders.

View full company profile

Therapeutic Areas

Epilepsy Migraine Anxiety Alzheimer's disease

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active
GABA-A PAM for Epilepsy	Modulate Bio	Preclinical	Active